Seung Bum Park
Seung Bum Park (박승범) is a South Korean organic chemist and chemical biologist, a professor and deputy director in the Chemistry Department at Seoul National University (SNU), and founder and CEO of SPARK Biopharma.
His research uses diversity-oriented synthesis and phenotypic screening to discover small-molecule therapeutic candidates, and he developed the ‘Seoul-Fluor’ fluorescent chemical scaffold used in bioimaging.
He is an elected Fellow of the Korean Academy of Science and Technology (KAST) and won the 20th Kyung-Ahm Prize in Natural Science (2024), a well-established Korean science prize.
Notability & Coverage Analysis
Park is the only subject among the ten where independent Korean-language news outlets (HelloDD.com and ChosunBiz) directly covered a specific award — his 2010 Presidential Young Scientist Award from the Korean Ministry of Education, Science and Technology — genuine independent journalistic coverage, not just an award-body listing.
The Kyung-Ahm Prize (2024) is a nationally recognized Korean science prize with a public foundation and laureate list, supporting WP:NPROF C2.
Election as a KAST Fellow (2025) is election to a national academy of science, one of the clearest WP:NPROF C3 signals in this entire batch.
Combined, this is a moderately strong case, though it would benefit from English-language independent coverage as well, since the current article is aimed at an English-reading Wikipedia audience but its independent sources are all in Korean.
Solutions
Existing Article Audit
Content
- Strongest fact-checking result in the batch: the flagship award claim is corroborated by two independent news outlets rather than one institutional page.
- The founder/CEO claim for SPARK Biopharma is asserted in the lead but not independently sourced in the current reference list; recommend adding a company-registry or press citation.
Sources
- Good mix of independent award-body and press sources; the main gap is the absence of any English-language independent coverage, not disqualifying but worth noting for readers checking sources without Korean fluency.
Compliance
- Verifiability: strong for the awards; weaker for the SPARK Biopharma claim.
- NPOV: neutral in tone.
- Notability: reasonably solid composite case (KAST fellow + national prize + dual-sourced press coverage of an earlier award).
Improvement Plan
- Add independent sourcing (company registry, press release, or news coverage) for the SPARK Biopharma founder/CEO claim.
- Note in-text that the HelloDD/ChosunBiz sources are in Korean, per Wikipedia’s guidance on non-English sources (WP:NONENG).
- Search for any English-language chemistry trade press coverage of the Kyung-Ahm Prize or the Seoul-Fluor work to broaden the English-reader-accessible source base.